Claims for Patent: 8,299,118

Summary for Patent: 8,299,118

Title:	Enhanced bimatoprost ophthalmic solution
Abstract:	A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
Inventor(s):	Chang; Chin-Ming (Tustin, CA), Chang; James N. (Newport Beach, CA), Schiffman; Rhett M. (Laguna Beach, CA), Jordan; R. Scott (Trabuco Canyon, CA), Chang-Lin; Joan-En (Tustin, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	13/370,529
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,299,118
Patent Claims:	1. A method of lowering intraocular pressure in a person with glaucoma or ocular hypertension, the method comprising administering once daily to an eye of the person a first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the method lowers intraocular pressure and results in less hyperemia as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 2. The method of claim 1 wherein the first composition has a pH of about 7.3. 3. The method of claim 1 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride. 4. The method of claim 1 wherein the first composition has at least one buffering agent selected from the group consisting of dibasic sodium phosphate heptahydrate, citric acid monohydrate and EDTA. 5. The method of claim 1 wherein the method is effective in treating glaucoma. 6. The method of claim 1 wherein the method is effective in treating ocular hypertension. 7. A method of lowering intraocular pressure in a person with glaucoma or ocular hypertension, the method comprising administering once daily to an eye of the person a first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the method lowers intraocular pressure without a substantial reduction in the intraocular pressure lowering benefit provided by the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 8. The method of claim 7 wherein the once daily administration of the first composition results in less hyperemia as compared to the once daily administration of the second composition. 9. The method of claim 7 wherein the first composition has a pH of about 7.3. 10. The method of claim 7 wherein the first composition is a solution. 11. The method of claim 7 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride. 12. The method of claim 7 wherein the first composition has at least one buffering agent selected from the group consisting of dibasic sodium phosphate heptahydrate, citric acid monohydrate and EDTA. 13. The method of claim 7 wherein the method is effective in treating glaucoma. 14. The method of claim 7 wherein the method is effective in treating ocular hypertension. 15. A method of reducing the amount of bimatoprost administered to a person in a treatment for glaucoma or ocular hypertension, comprising administering once daily to an eye of the person a first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the composition remains useful in treating glaucoma or ocular hypertension despite a lower concentration of bimatoprost as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 16. The method of claim 15 wherein the once daily administration of the first composition results in less hyperemia as compared to the once daily administration of the second composition. 17. The method of claim 15 wherein the first composition has a pH of about 7.3. 18. The method of claim 15 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride. 19. The method of claim 15 wherein the first composition is applied topically. 20. The method of claim 15 wherein the method is effective in treating glaucoma. 21. The method of claim 20 wherein the glaucoma is open-angle glaucoma. 22. The method of claim 15 wherein the method is effective in treating ocular hypertension. 23. A method of reducing the amount of bimatoprost administered to a person in a treatment for glaucoma or ocular hypertension, comprising administering once daily to an eye of the person a first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the benzalkonium chloride concentration of the first composition increases the permeability of bimatoprost across corneal epithelial cell layers as compared to once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 24. The method of claim 23 wherein the first composition remains useful in treating glaucoma or ocular hypertension despite a lower concentration of bimatoprost as compared to the second composition. 25. The method of claim 23 wherein the once daily administration of the first composition results in less hyperemia as compared to the once daily administration of the second composition. 26. The method of claim 23 wherein the method is effective in treating glaucoma. 27. The method of claim 23 wherein the method is effective in treating ocular hypertension. 28. The method of claim 23 wherein the first composition has a pH of about 7.3. 29. The method of claim 23 wherein the first composition has at least one buffering agent selected from the group consisting of dibasic sodium phosphate heptahydrate, citric acid monohydrate and EDTA. 30. The method of claim 23 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride.